TransMedics Group, Inc. Aktie News

ANDOVER, Mass. , Nov. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference at the ...

The health industry offers opportunities beyond the big, well-known names. TransMedics Group boasts a sticky business model that is highly profitable.

During the third quarter of 2025, the U.S. Small Cap Growth Composite Portfolio returned 21.4% gross and 21.1% net of fees. Bloom Energy is a provider of solid oxide fuel cells that play a critical role in delivering clean, reliable, 'always on' power at scale. Oddity Tech is a digital beauty and wellness platform that uses AI and data science to develop and recommend personalized products base...

ANDOVER, Mass. , Oct. 31, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 27, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 27,582 shares of its common stock and an ...

TransMedics delivered solid year-over-year growth in Q3, despite seasonal weakness and concerns over U.S. liver market saturation. The next-gen heart and lung trials, along with an increased focus on international expansion, will be supportive of growth going forward. While TransMedics faces margin headwinds in the short term, profitability continues to improve and will be supportive of the com...

TransMedics shares dropped after Q3 results beat consensus but missed high investor expectations, creating a favorable entry point. Q3 is seasonally weak for TMDX, but the current selloff makes valuation attractive and expectations more reasonable. Industry data signals a strong Q4 ahead, supporting the case for near-term upside in TMDX.

TransMedics Group, Inc. ( TMDX ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Waleed Hassanein - Founder, President, CEO & Director Gerardo Hernandez - CFO & Treasurer Conference Call Participants Dorothy Morgan - Gilmartin Group LLC K. Gong - JPMorgan Chase & Co, Research Division William Plovanic - Canaccord Genuity Corp., Research Division Matthew Mardula - William...

ANDOVER, Mass. , Oct. 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2025.